Hanane Touil, Antonia Kobert, Nathalie Lebeurrier, Aja Rieger, Philippe Saikali, Caroline Lambert, Lama Fawaz, Craig S Moore, Alexandre Prat, Jennifer Gommerman, Jack P Antel, Yasuto Itoyama, Ichiro Nakashima, Amit Bar-Or
BACKGROUND: The success of clinical trials of selective B cell depletion in patients with relapsing multiple sclerosis (MS) indicates B cells are important contributors to peripheral immune responses involved in the development of new relapses. Such B cell contribution to peripheral inflammation likely involves antibody-independent mechanisms. Of growing interest is the potential that B cells, within the MS central nervous system (CNS), may also contribute to the propagation of CNS-compartmentalized inflammation in progressive (non-relapsing) disease...
April 19, 2018: Journal of Neuroinflammation